Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;14(6):1443-1455.
doi: 10.1007/s13555-024-01185-1. Epub 2024 May 30.

A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis

Affiliations
Review

A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis

Paolo Amerio et al. Dermatol Ther (Heidelb). 2024 Jun.

Abstract

Atopic dermatitis (AD) is a highly heterogeneous chronic inflammatory skin disorder that is frequently associated with a plethora of comorbidities. AD is, therefore, considered a systemic disease impacted by a considerable burden and leading to poor quality of life, especially in patients with moderate-to-severe disease. Since atopic and non-atopic comorbidities can further worsen the disease course, accurate establishment of the patient's individual intrinsic risk profile and needs is crucial and may help in guiding the selection of the best treatment option. Better quality of care for patients with AD can be delivered through a multidisciplinary team led by a dermatologist, for comprehensive patient management. The implementation of a multidisciplinary approach for AD could enhance the delivery of optimised and safe treatments, improve the standard of care and patient outcomes in the short and long term, and prevent or delay the lifelong impact of uncontrolled AD. Understanding the unmet needs, assessing correctly the patient risk profile and enhancing the shared patient-physician decision-making process can lead to disease control and quality-of-life improvement, especially in the context of the introduction of newer treatment for AD. This narrative review is a call for more data to establish standardised patient profiles and multidisciplinary strategies in AD management. In view on the fast-evolving treatments for AD, this review aims at highlighting the importance of a multidisciplinary approach to a comprehensive assessment and holistic care in patients with moderate-to-severe AD.

Keywords: Holistic care; Moderate-to-severe atopic dermatitis; Multidisciplinary approach.

PubMed Disclaimer

Conflict of interest statement

Paolo Amerio: acted as investigator, consultant and speaker for AbbVie, Eli Lilly, Sanofi, Galderma, Pfizer, Novartis, Leo Pharma; Silvia Mariel Ferrucci: acted as a principal investigator in clinical trials for AbbVie, Galderma, Amgen, Sanofi, Eli Lilly, Almirall, Novartis, Bayer and as a speaker and advisor for AbbVie, Almirall, Leo Pharma, Pfizer, Novartis, Menarini, Sanofi, Lilly; Marco Galluzzo: acted as a speaker and/or consultant for AbbVie, Almirall, Eli-Lilly, Janssen-Cilag, LeoPharma, Novartis, Sanofi, and acted as a principal investigator in clinical trials for Almirall, Incyte Corporation, Janssen-Cilag, LeoPharma, outside the submitted work; Maddalena Napolitano: acted as speaker, consultant and/or advisory board member for AbbVie, Eli Lilly, Leo Pharma, Novartis, and Sanofi; Alessandra Narcisi: acted as investigator, consultant, speaker and/or advisory board member for AbbVie, Eli Lilly, Novartis, UCB, Almirall, Leo Pharma, Pfizer, Sanofi, Janssen; Cataldo Patruno: acted as investigator, speaker, consultant, and/or advisory board member for AbbVie, Amgen, Eli Lilly, Galderma, Leo Pharma, Novartis, Pfizer, Pierre Fabre, and Sanofi; Mariateresa Rossi: acted as investigator, speaker, consultant, and/or advisory board member for AbbVie, Sanofi, Eli Lilly, Galderma, Leo Pharma, Pfizer, L’Oréal Paris; Anna Levi, Sara Di Fino, Chiara Palladino: employees of AbbVie and may own AbbVie stocks/options.

Similar articles

Cited by

References

    1. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi: 10.1038/s41572-018-0001-z. - DOI - PubMed
    1. Bylund S, Kobyletzki LB, Svalstedt M, Svensson A. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):adv00160. doi: 10.2340/00015555-3510. - DOI - PMC - PubMed
    1. Carrascosa JM, de la Cueva P, de Lucas R, Fonseca E, Martin A, Vicente A, et al. Patient journey in atopic dermatitis: the real-world scenario. Dermatol Ther (Heidelb) 2021;11(5):1693–1705. doi: 10.1007/s13555-021-00592-y. - DOI - PMC - PubMed
    1. Stander S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136–1143. doi: 10.1056/NEJMra2023911. - DOI - PubMed
    1. Lobefaro F, Gualdi G, Di Nuzzo S, Amerio P. Atopic dermatitis: clinical aspects and unmet needs. Biomedicines. 2022;10(11):2927. doi: 10.3390/biomedicines10112927. - DOI - PMC - PubMed

LinkOut - more resources